影像科学与光化学 ›› 2022, Vol. 40 ›› Issue (4): 888-892.DOI: 10.7517/issn.1674-0475.220125

• 综述与论文 • 上一篇    下一篇

超声评估α1-受体阻滞剂联合5α-睾酮还原酶抑制剂治疗良性前列腺增生的效果

关义满1, 房勤茂1, 邓荷萍1, 张巍巍1, 武霞2, 张博2   

  1. 1. 河北医科大学第三医院超声科, 河北 石家庄 050000;
    2. 河北医科大学第三医院老年病科, 河北 石家庄 050000
  • 收稿日期:2022-01-14 发布日期:2022-07-09
  • 通讯作者: 关义满
  • 基金资助:
    河北省2016年医学科学研究重点课题计划(20160584)

Ultrasound Evaluation of α1-Receptor Blocker Combined with 5α-Testosterone Reductase Inhibitor in the Treatment of Benign Prostatic Hyperplasia

GUAN Yiman1, FANF Qinmao1, DENG Heping1, ZHANG Weiwei1, WU Xia2, ZHANG Bo2   

  1. 1. Department of Ultrasound, The Third Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, P. R. China;
    2. Department of Geriatrics, The Third Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, P. R. China
  • Received:2022-01-14 Published:2022-07-09

摘要: 本文以探究α1-受体阻滞剂联合5α-睾酮还原酶抑制剂治疗良性前列腺增生患者前列腺体积、内循环及组织硬度的超声评估为主要目的。选取100例良性前列腺增生患者为研究对象,随机分为对照组(50例)和联合组(50例)。两组均进行常规治疗,对照组给予患者5α-睾酮还原酶抑制剂进行治疗,联合组给予患者5α-睾酮还原酶抑制剂与α1-受体阻滞剂联合治疗。通过彩色多普勒超声检测患者的前列腺体积(PV),根据弹性成像来评估组织硬度,并检测残余尿量(PVR)、最大自由尿流率(Qmax)、前列腺特异性抗原(PSA)。观察良性前列腺增生相关指标的变化,并统计治疗效果。治疗后,联合组IPSS评分、PV、PVR、PSA均低于对照组,QOL评分、Qmax高于对照组(P<0.05)。联合组治疗效果总有效率较高(P<0.05)。α1-受体阻滞剂、5α-睾酮还原酶抑制剂结合治疗可以改善良性前列腺增生患者前列腺体积、内循环、组织硬度,促进患者康复。

关键词: α1-受体阻滞剂, 5α-睾酮还原酶抑制剂, 良性前列腺增生, 前列腺体积, 组织硬度

Abstract: This paper aimed to explore the ultrasound evaluation of prostate volume, internal circulation and tissue hardness combined with α1-receptor blocker and 5α-testosterone reductase inhibitor in patients with benign prostatic hyperplasia. 100 cases of patients with benign prostatic hyperplasia were selected as research objects and randomized into 50 in the control group and 50 in the combination group. All patients were routinely treated, the patients in control group were given the patient 5α-testosterone reductase inhibitor, while the combination group were given 5α-testosterone reductase inhibitor combined with α1-receptor blocker. The patient's prostate volume was evaluated by color Doppler ultrasound test, according to elastography to assess tissue hardness, and detected the post void residual (PVR), the maximum flow rate (Qmax), prostate specific antigen (PSA). The changes of benign prostatic hyperplasia were observed and the treatment effect was counted. After treatments the IPSS score, PV, PVR and PSA of the combination group were lower than the control group, and QOL score and Qmax were higher than the control group (P<0.05). The total response rate of the combination group was higher (P<0.05). The combination of α1-receptor blocker and 5α-testosterone reductase inhibitor can improve prostate volume, internal circulation, and tissue hardness in patients with benign prostatic hyperplasia to promote patient recovery.

Key words: α1-blockers, 5α-testosterone reductase inhibitor, benign prostatic hyperplasia, prostate volume, tissue hardness